# Medication Production Readiness — Phase M1.1B

**Program:** Enterprise Medication Governance  
**Phase:** M1.1B (audit only)  
**Date:** 2026-05-31  

Consolidates **Parts 11–13** and executive readiness decision.

**Related audits:**

- [medication-data-quality-audit.md](./medication-data-quality-audit.md)
- [medication-controlled-substance-audit.md](./medication-controlled-substance-audit.md)
- [medication-safety-governance-audit.md](./medication-safety-governance-audit.md)
- [medication-inventory-architecture-audit.md](./medication-inventory-architecture-audit.md) (M1.1A)

---

## Executive decision

| Question | Answer |
|----------|--------|
| Reuse existing Haiti medication directory? | **Yes** (M1.1A confirmed) |
| Production enterprise medication governance ready? | **No** |
| **SAFE / NOT SAFE** | **NOT SAFE** for enterprise safety governance sign-off; **SAFE (conditional)** for legacy MVP catalog use after production count check |

---

## Part 11 — Production readiness scores

Scores reflect **local dev DB** + code audit. Production verification would adjust ±10 points.

| Domain | Score (0–100) | Drivers |
|--------|---------------|---------|
| **Medication Catalog Readiness** | **62** | Unique codes; 263 Haiti seed; bilingual labels; 299 active legacy rows; −15 for 52 missing generics, +36 import drift, canonical inactive |
| **Search Readiness** | **52** | Metformin/Lasix/Tylenol work; −20 warfarin/coumadin absent; −15 misspellings; −10 baseline noise on acetaminophen search |
| **Safety Governance Readiness** | **12** | 0 high-alert profiles; 0 LASA groups; 55% controlled audit list presence; inconsistent benzo flags |
| **Order Workflow Readiness** | **48** | Orders + partial MAR; no frequency/PRN/eMAR/pharmacy verification |
| **Enterprise Medication Readiness** | **44** | Weighted mean of above (equal weight) |

### Score rubric (summary)

- **80–100:** Production enterprise ready  
- **60–79:** MVP ready with documented gaps  
- **40–59:** Partial — governance program required  
- **0–39:** Not ready  

**Enterprise Medication Readiness = 44** → **Partial / not production-ready** for governance program closure.

---

## Part 12 — Risk register (top 10)

| # | Risk | Severity | Mitigation | Phase |
|---|------|----------|------------|-------|
| 1 | Zero `MedicationSafetyProfile.isHighAlert` despite high-risk catalog drugs | **CRITICAL** | Clinical HA manifest + profile backfill | M1.4 |
| 2 | Production medication counts/governance **not verified** | **HIGH** | Operator read-only SQL replay | M1.1B ops |
| 3 | Controlled substance flags incomplete (diazepam, tramadol, oral lorazepam) | **HIGH** | Policy sign-off + seed/catalog update | M1.3 |
| 4 | 45% of M1.1B controlled audit list absent (oxycodone, hydrocodone, etc.) | **HIGH** | Formulary gap analysis vs Haiti needs | M1.3 |
| 5 | Dual catalog: 676 inactive canonical products vs 299 legacy active | **HIGH** | Architecture consolidation plan | M1.6 |
| 6 | Alias collisions (`rsi`, `sédation`, `intubation`) → wrong drug pick | **HIGH** | Alias governance + search disambiguation | M1.5 |
| 7 | Warfarin / Coumadin not in catalog — anticoagulant gap | **HIGH** | Add to seed or document intentional omission | M1.3 / M1.2 |
| 8 | Search misspellings fail (no fuzzy match) | **MEDIUM** | Expand alias map or fuzzy tier | M1.5 |
| 9 | Free-text route/form (FR/EN mix, `Tablet` vs `comprimé`) | **MEDIUM** | Route/form normalization taxonomy | M1.2 |
| 10 | Global baseline import rows pollute search (`19G1-ACET-*`) | **MEDIUM** | Activation governance + import hygiene | M1.6 / M1.5 |

---

## Part 13 — Recommended next phase

### Recommendation: **M1.3 — Controlled Substance Governance**

### Justification

1. **Patient safety and regulatory exposure** outweigh taxonomy polish — local audit shows **inconsistent controlled flags** on substances that **exist** (diazepam, tramadol, oral lorazepam) while IV opioids are flagged.
2. **55% catalog presence** on the M1.1B controlled audit list with **0% safety profile** coverage — controlled governance is the highest-severity **data** gap before high-alert seeding.
3. High-alert **soft rules** already fire in UI for some agents, but **persisted governance** is empty — M1.3 establishes the **safety profile pipeline** that M1.4 can extend for `isHighAlert` and LASA.
4. M1.2 (taxonomy) and M1.5 (search) are important but **do not** address wrong controlled classification on drugs already orderable today.

### Alternatives considered

| Phase | Why not first |
|-------|----------------|
| **M1.2 Taxonomy** | Needed long-term; does not fix immediate controlled misclassification |
| **M1.4 High-alert** | Depends on safety profile population started in M1.3 |
| **M1.5 Search** | Warfarin gap is formulary/content; search cannot fix missing rows |
| **M1.6 Consolidation** | Large effort; should follow signed controlled/HA manifests |

### After M1.3

Proceed **M1.4** (high-alert + LASA data), then **M1.5** (search/alias), then **M1.2** / **M1.6** as needed.

---

## Production verification checklist (operator)

Before any production seed or governance change:

- [ ] Run read-only counts (Part 1 table) on production `DATABASE_URL`
- [ ] Re-run controlled substance table (11 agents)
- [ ] Re-run high-alert table (10 agents)
- [ ] Compare production `CatalogMedication` count to **263** Haiti seed
- [ ] Document delta rows (imports, baseline codes)
- [ ] Sign clinical manifest for controlled schedules (Haiti)

---

## M1.1B return summary

| Item | Result |
|------|--------|
| Medication counts | Legacy: **299** active; aliases **344**; concepts **686** (5 active); products **676** (0 active); packages **676** (5 active) — **LOCAL DEV** |
| Duplicate findings | 0 dup codes; 61 dup generic groups (mostly valid SKUs); 40 shared alias strings (**HIGH**) |
| Controlled coverage | **55%** presence; **50%** strict flag accuracy; **0%** safety profiles — **PARTIAL** |
| High-alert coverage | **90%** catalog presence; **0%** profile flags — **FAIL** |
| LASA | Schema yes; data **0** — **NOT IMPLEMENTED** |
| Search quality | **PARTIAL** |
| Workflow quality | Orders **IMPLEMENTED**; frequency/PRN/eMAR **NOT IMPLEMENTED** |
| Governance gaps | HA/LASA **MISSING**; controlled **PARTIAL** |
| Readiness scores | Catalog 62, Search 52, Safety 12, Orders 48, Enterprise **44** |
| Recommended next phase | **M1.3 Controlled Substance Governance** |
| **SAFE / NOT SAFE** | **NOT SAFE** (enterprise governance); **SAFE (conditional)** (legacy MVP catalog) |

---

## Git

No commit in M1.1B. When approved:

```bash
git add docs/medications/*.md
git commit -m "Audit medication data quality and governance"
```

---

## Sign-off

| Role | Status |
|------|--------|
| M1.1B audit | **COMPLETE** |
| Production DB verification | **Outstanding** |
